Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Streptococcus salivarius K12 for prevention of radiotherapy-induced oral mucositis in head and neck squamous cell carcinoma
ChiCTR2100054689Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2021
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Streptococcus salivarius K12 in head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Oral mucositis grade. Started Dec 2021; status: recruiting.
02
Drugs
Streptococcus salivarius K12
03
Conditions
head and neck squamous cell carcinoma (HNSCC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2100054689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054689.